Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a prospective open-label study
Not Applicable
Completed
- Conditions
- schizophrenia
- Registration Number
- JPRN-jRCT1091220245
- Lead Sponsor
- Keiko Naono
- Brief Summary
The hyperprolactinemia and other clinical conditions could be improved by the partial replacing to ARP, without no side effect.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion criteria were a diagnosis of schizophrenia or a diagnosis in the range of schizophrenia (F2) according to the International Classification of Diseases, version 10 (ICD-10) by a psychiatrist.
Exclusion Criteria
Exclusion criteria were: 1) risk factors that could possibly influence prolactin level (e.g., patients with a prolactin-producing tumor or an endocrine disease such as thyroid disease, and pregnant or lactating female patients), 2) lack of study cooperation or unreliable data, and 3) factors that could possibly influence blood glucose level (e.g., patients with diabetes mellitus).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum prolactin
- Secondary Outcome Measures
Name Time Method Global Assessment of Functioning (GAF) , the Clinical Global Impression of Improvement (CGI-I) scale, body weight, and blood glucose level